Analgesic Solutions and its collaborators have had the privilege of making many contributions to the field of Analgesic Drug Development.
Our current areas of focus are development and validation of improved methods for conducting efficient proof of concept trials; opioids; risk management.
See selected publications for a sampling of our work or feel free to contact us if you would like to discuss any of our research services.
Akbik H, Butler SF, Budman S, Fernandez K, Katz NP, Jamison RN. Validation and clinical application of the Screener and Opioid Assessment for Patients with Pain (SOAPP). J Pain Sym Manage, 2006 (in press).
Butler, S.F., Benoit, C.M., Budman, S.H., Fernandez, K.C., McCormick, C., Wing Venuti, S., and Katz N. (In Press). Development and validation of an opioid attractiveness scale: a novel measure of the attractiveness of opioid products to potential abusers. Harm Reduct J. 2006 Feb 2;3(1):5.
Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Wernicke J, Witter J. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005 Jan;113(1-2):9-19.
Katz N. Methodological issues in clinical trials of opioids for chronic pain. Neurology. 2005 Dec 29;65(12 Suppl 4):S32-49.
White AG, Birnbaum HG, Mareva MN, Daher M, Vallow S, Schein J, Katz N. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm. 2005 Jul-Aug;11(6):469-79. Katz N, Rodgers D, Krupa D. Onset of efficacy of rofecoxib in the treatment of chronic low back pain. Current Research and Medical Opinion 2004 May;20(5):651-8.
Passik SD, Kirsh KL, Whitcomb L, Portenoy RK, Katz NP, Kleinman L, Dodd SL, Schein JR. A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy. Clin Ther. 2004 Apr;26(4):552-61.
Katz NP, Shapiro DE, Herrmann TE, Kost J, Custer LM. Rapid onset of cutaneous anesthesia with EMLA cream after pretreatment with a new ultrasound-emitting device. Anesth Analg. 2004 Feb;98(2):371-6, table of contents.
Battisti WP, Katz NP, Weaver AL, Matsumoto AK, Kivitz AJ, Polis AB, Geba GP. Pain management in osteoarthritis: a focus on onset of efficacy--a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials. J Pain. 2004 Nov;5(9):511-20.
Argoff CE, Katz N, Backonja M. Treatment of postherpetic neuralgia: a review of therapeutic options. J Pain Symptom Manage. 2004 Oct;28(4):396-411.
Reynolds L, Rauck R, Webster L, DuPen S, Heinze E, Portenoy R, Katz N, Charapata S, Wallace M, Fisher DM. Relative analgesic potency of fentanyl and sufentanil during intermediate-term infusions in patients after long-term opioid treatment for chronic pain. Pain. 2004 Jul;110(1-2):182-8.
Katz N. Reporting of clinical trials of analgesia. J Thorac Cardiovasc Surg. 2004 Feb;127(2):605; author reply 606.
Katz N, Ju WD, Krupa DA, Sperling RS, Bozalis Rodgers D, Gertz BJ, Gimbel J, Coleman S, Fisher C, Nabizadeh S, Borenstein D; The Vioxx Chronic Low Back Pain Study Group. Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials. Spine. 2003 May 1;28(9):851-9.
Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, Cleeland C, Dionne R, Farrar JT, Galer BS, Hewitt DJ, Jadad AR, Katz NP, Kramer LD, Manning DC, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robinson JP, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Witter J. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain. 2003 Dec;106(3):337-45.
Jamison RN, Schein JR, Vallow S, Ascher S, Vorsanger GJ, Katz NP. Neuropsychological effects of long-term opioid use in chronic pain patients. J Pain Symptom Manage. 2003 Oct;26(4):913-21.
Katz NP, Sherburne S, Beach M, Rose RJ, Vielguth J, Bradley J, Fanciullo GJ. Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg. 2003 Oct;97(4):1097-102.
Jamison R, Gracely R, Raymond S, Levine J, Marino B, Herrmann T, Daly M, Fram D, Katz N. Comparative study of electronic vs. paper VAS ratings: a randomized, crossover trial using healthy volunteers.
Pain. 2002 Sep;99(1-2):341.
Katz N. The impact of pain management on quality of life.
J Pain Symptom Manage. 2002 Jul;24(1 Suppl):S38.
Katz NP, Gammaitoni AR, Davis MW, Dworkin RH, and the Lidoderm Patch Study Group. Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trial. Pain Medicine 3, 2002.
Katz N. Coxibs: Evolving role in pain management. Semin Arthritis Rheum 32:15-24, 2002.
Wallace MS, Rowbotham MC, Katz NP, Dworkin RH, Dotson RM, Galer BS, Rauck RL, Backonja MM, Quessy SN, Meisner PD. A randomized, double-blind, placebo-controlled trial of a glycine antagonist in neuropathic pain. Neurology. 2002 Dec 10;59(11):1694-700.
Katz N, Fanciullo GJ. Role of urine toxicology testing in the management of chronic opioid therapy. Clin J Pain. 2002 Jul-Aug; 18 (4 Suppl) :S76-82.
Jamison RN, Raymond SA, Levine JG, Slawsby EA, Nedeljkovic SS, Katz NP. Electronic diaries for monitoring chronic pain: 1-year validation study. Pain. 2001 Apr;91(3):277-85.
Jamison, RN, Kauffman J, Katz N. Characteristics of methadone maintenance patients with chronic pain. J Pain Sympt Manage 2000;19:53-62.